Business
Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer
FOSTER CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global
About this update from Vaxcyte, Inc.
[{"type":"text","content":"FOSTER CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the promotion of Andrew Guggenhime from Chief Financial Officer and Chief Business Officer to President and Chief Financial Officer effective January 1, 2021. In this new role, Mr. Guggenhime will lead the finance, human resources, corporate communications, investor relations, business and corporate development, strategy, information technology and facilities activities at Vaxcyte. “Andrew has demonstrated his outstanding leadership capabilities since joining Vaxcyte earlier this year, and brings significant experience across a wide range of functions,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “Today's announcement reflects an evolution in our leadership structure which enables us to continue to scale our organization effectively as we execute on our mission and advance our pipeline of novel vaccine candidates, led by VAX-24, our pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease.” Mr. Guggenhime joined Vaxcyte in May 2020, bringing more than two decades of finance, strategic and operational leadership experience at both private and public healthcare companies. Mr. Guggenhime joined Vaxcyte from Dermira, Inc., where he served as Chief Financial Officer from April 2014 through the acquisition of the company by Eli Lilly and Company in February 2020. Prior to Dermira, Mr. Guggenhime served as Chief Financial Officer for CardioDx, Inc., a privately held commercial-stage cardiovascular molecular diagnostics company. He also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc., a privately held, development-stage company, which was acquired by Gilead Sciences, Inc. in 2011, and as Chief Financial Officer for Facet Biotech Corporation, a biotechnology company that was acquired by Abbott Laboratories in April 2010. He previously served as Chief Financial Officer of PDL BioPharma, Inc. until Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Facet Biotech, Mr. Guggenhime served as Chief Financial Officer for...